These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6445060)

  • 1. [Immunotherapy in multiple sclerosis].
    Cendrowski W
    Pol Tyg Lek; 1980 Mar; 35(9):237-8. PubMed ID: 6445060
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological aspects of multiple sclerosis.
    Hughes RA
    Br J Hosp Med; 1977 Nov; 18(5):467-8, 470, 473-6. PubMed ID: 597658
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: Immunologic studies with transfer factor in multiple sclerosis patients.
    Zabriskie JB; Utermohlen V; Espinoza LR; Plank CR; Collins RC
    Neurology; 1975 May; 25(5):490. PubMed ID: 1169711
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.
    Bourdette DN; Whitham RH; Chou YK; Morrison WJ; Atherton J; Kenny C; Liefeld D; Hashim GA; Offner H; Vandenbark AA
    J Immunol; 1994 Mar; 152(5):2510-9. PubMed ID: 7510746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer factor in transplantation immunobiology.
    Lawrence HS
    Transplant Proc; 1977 Mar; 9(1):1319-26. PubMed ID: 141127
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppression, transfer factor, and multiple sclerosis.
    Lancet; 1980 Nov; 2(8205):1191-2. PubMed ID: 6107790
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings: Transfer factor treatment in multiple sclerosis.
    Fog T; Jersild C; Dupont B; Platz PJ; Svejgaard A; Thomsen M; Midholm S; Raun NE
    Neurology; 1975 May; 25(5):489-90. PubMed ID: 1169710
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prospects of an immunologic therapy of multiple sclerosis].
    Fasanaro G; Gentile A; Stella L
    Acta Neurol (Napoli); 1972; 27(4):367-78. PubMed ID: 5085161
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of multiple sclerosis using transfer factor].
    Nejtek P; St'ovícek J
    Cesk Neurol Neurochir; 1986 Nov; 49(6):419-20. PubMed ID: 3802255
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

  • 11. Transfer factor treatment of multiple sclerosis. A pilot study.
    Jersild C; Platz P; Svejgaard A; Pedersen L; Kam-Hansen S; Raun N; Mellerup E; Jacobsen B; Linnemann F; Westh P
    Acta Neurol Scand Suppl; 1977; 63():253-64. PubMed ID: 322441
    [No Abstract]   [Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
    Karussis D; Slavin S
    J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical application of transfer factor, lymphokines and thymic factor].
    Hori M
    Nihon Rinsho; 1983; 41(4):857-67. PubMed ID: 6350654
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunotherapy of multiple sclerosis].
    Nervenarzt; 1997 Sep; 68(9 Suppl):1-8. PubMed ID: 9380221
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
    Stinissen P; Raus J
    Acta Neurol Belg; 1999 Mar; 99(1):65-9. PubMed ID: 10218096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
    Katsara M; Deraos G; Tselios T; Matsoukas MT; Friligou I; Matsoukas J; Apostolopoulos V
    J Med Chem; 2009 Jan; 52(1):214-8. PubMed ID: 19072222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressor cell response in multiple sclerosis.
    Wallen WC; Traub RG
    Trans Am Neurol Assoc; 1979; 104():111. PubMed ID: 162253
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thymus-dependent therapeutic immunosuppression in multiple sclerosis and myasthenia].
    Lobzin VS; Golovkin VI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(2):176-81. PubMed ID: 7072415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.